· Published by Health Canada · Official notice
This is duplicated text of a letter from GlaxoSmithKline Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
August 6, 2013
Dear Health Care Professional:
Subject: VOTRIENT® (pazopanib hydrochloride) - Important Change to Frequency of Serum Liver Test Monitoring for Hepatotoxicity
GlaxoSmithKline Inc., in consultation with Health Canada, would like to inform you of an important safety update to the Warnings & Precautions section of the Product Monograph for VOTRIENT®, regarding a change in frequency of serum liver test monitoring for hepatotoxicity.
VOTRIENT® is a tyrosine kinase inhibitor indicated for the treatment of patients with metastatic renal cell (clear cell) carcinoma as first-line systemic therapy or as second line systemic therapy after treatment with cytokines for metastatic disease.
It is also indicated for the treatment of patients with selective subtypes of advanced soft tissue sarcoma who have received prior chemotherapy for metastatic disease, or who have progressed within 12 months after (neo) adjuvant therapy.
Elevated Serum Liver Tests should be managed as described below and in the Product Monograph (see WARNINGS AND PRECAUTIONS, Hepatic Effects):
The revised Product Monograph for VOTRIENT® may be accessed on the Health Canada Web Site, or on the Canadian Web Site of GlaxoSmithKline.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or other serious or unexpected adverse reactions in patients receiving VOTRIENT® should be reported to GlaxoSmithKline or Health Canada.
NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Tel: 1-800-387-7374
To correct your mailing address or fax number, contact GlaxoSmithKline Inc.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
If you have any questions about this new information, please contact GlaxoSmithKline Medical Information Department at 1-800-387-7374.
Sincerely,
original signed by
Dr. Glenn Crater,
Vice-President, Medical and Chief Medical Officer
GlaxoSmithKline Inc.
VOTRIENT® is a registered trademark, used under license by GlaxoSmithKline Inc.